AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00651456
Drug: Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation D1 (D1=D22, 6 cycles)~* Cisplatin 75 mg/m2 D1 (D1=D22, 6 cycles)~* Bevacizumab 15 mg/kg D1 (D1=D22, until progression)
Trial: NCT02354586
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03099174
Drug: Xentuzumab
RxNorm normalized name: Xentuzumab
DrugBank: Xentuzumab (DB14871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly administrated through one hour intravenous infusion
Trial: NCT03919071
Drug: Dabrafenib Mesylate
RxNorm normalized name: dabrafenib mesylate
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03919071
Drug: Trametinib Dimethyl Sulfoxide
RxNorm normalized name: Trametinib Dimethyl Sulfoxide
DrugBank: Dimethyl sulfoxide (DB01093)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02249442
Drug: Tipranavir (TPV)
DrugBank: Tipranavir (DB00932)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02249442
Drug: Ritonavir (r)
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04106219
Drug: LY3295668 Erbumine
RxNorm normalized name: Perindopril Erbumine
DrugBank: Erbumine (DB18019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04106219
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT01815242
Drug: nab-Paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01815242
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01815242
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02714439
Drug: Proflavine
RxNorm normalized name: proflavine
DrugBank: Proflavine (DB01123)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proflavine 0.01% applied to the cervix before high-resolution microendoscopy imaging procedure performed.
Trial: NCT01608009
Drug: Pazopanib and paclitaxel
RxNorm normalized name: paclitaxel and encequidar
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pazopanib 800mg od for 7 days, followed by 18 weeks of combination therapy (paclitaxel 80mg/m2 weekly and pazopanib 800mg od). Following the completion of combination therapy, patients will continue on maintenance pazopanib 800mg od until disease progression.
Trial: NCT00195273
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mg loading dose, followed by 5 mg/day to achieve target trough levels of 10-15 ng/mL at months 1-6, then 8-12 ng/mL at months 7-12
Trial: NCT00195273
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose of 10 mg/kg/day, then twice daily to achieve target trough levels of 300-400 ng/mL at weeks 0-4; 200-300 ng/mL at months 1-2; 150-250 ng/mL at months 2-3; 100-200 ng/mL at months 3-6; 75-150 ng/mL months 6-12
Trial: NCT00195273
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 g twice daily; may be reduced to 750 mg BID for adverse events, or to 500 mg BID for persisting adverse events
Trial: NCT00195273
Drug: daclizumab
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV: 1 mg/kg to a maximum of 100 mg/dose. 5 doses at 2, 4, 6, and 8 weeks after transplantation
Trial: NCT02186873
Drug: Golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive 2mg/kg of intravenous infusions of golimumab .
Trial: NCT01680965
Drug: Ofatumumab
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase I: test an escalating dose of ofatumumab at cohorts of 300 mg, 700 mg, and 1000 mg given on day 0 and 14 of study.~Phase II: Ofatumumab MTD on day 0 and 14; patients will be followed for total of 24 months (months 1, 3, 6, 12 after therapy, then at 18 and 24 months following therapy)
Trial: NCT04750603
Drug: Fluticasone furoate (FF)/Vilanterol (VI)
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with a positive exercise challenge test were allocated to a single administration of salbutamol (400 µg) and 22 to FF/VI (92/22 µg) in a double blind, double dummy method to assess the short-term effect on exercise induced complaints
Trial: NCT04750603
Drug: Salbutamol
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with a positive exercise challenge test were allocated to a single administration of salbutamol (400 µg) and 22 to FF/VI (92/22 µg) in a double blind, double dummy method to assess the short-term effect on exercise induced complaints.
Trial: NCT02187705
Drug: Telmisartan tablets
RxNorm normalized name: Telmisartan Tablets
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients were treated with different doses of telmisartan for 14 days
Trial: NCT01484041
Drug: Dovitinib
RxNorm normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dovitinib at the recommended Phase 2 dose for 5 consecutive days followed by a 2-day rest
Trial: NCT00161473
Drug: prazosin
RxNorm normalized name: Prazosin
DrugBank: Prazosin (DB00457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants taking prazosin. Prazosin was administered as 1 or 2 mg capsules. Doses were initiated at 1 mg at bedtime. Titration based on tolerability was conducted up to a dose of 2 mg in the morning plus 4mg at bedtime.~Duration was 8 weeks.
Trial: NCT04342273
Drug: KW-6356
RxNorm normalized name: KW-7158
DrugBank: KW-6356 (DB17080)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-6356 will be administered once daily as therapeutic at Day 1 through Day 7
Trial: NCT04342273
Drug: KW-6356
RxNorm normalized name: KW-7158
DrugBank: KW-6356 (DB17080)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-6356 will be administered once daily as supratherapeutic dose at Day 1 through Day 7
Trial: NCT04342273
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo will be administered once daily at Day 1 through Day 6, followed by Moxifloxacin once daily at Day 7.
Trial: NCT00632840
Drug: Atorvastatin and fenofibrate
RxNorm normalized name: Atorvastatin and fenofibrate only product
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atorvastatin (40mg/day) fenofibrate (200mg/day)
Trial: NCT03099174
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment/28-day cycle p.o. Q12H on Days 1-28 (dose determined in Cohort A) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours
Trial: NCT03099174
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once a day
Trial: NCT03099174
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once a day
Trial: NCT00508222
Drug: Kaletra Tablets
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Kaletra 800/200 OD
Trial: NCT00579592
Drug: Campath-1H, rituximab, myfortic
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Campath-1H 30mg IV x 2 doses, rituximab 375mg/m2 IV x 1 dose, myfortic 720mg bid, cyclosporine po bid (target trough 200ng/ml) x 10-20 days
Trial: NCT02125188
Drug: Desmopressin
RxNorm normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Desmopressin 3ug/kg ivdrip before surgery
Trial: NCT02125188
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: saline 100ml ivdrip before surgery
Trial: NCT01319682
Drug: Intravenous lidocaine injection
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
Trial: NCT01319682
Drug: Intravenous normal saline injection
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in Group C (placebo control group) received normal saline intravenous injection
Trial: NCT01292109
Drug: sodium picosulphate
RxNorm normalized name: Sodium Picosulfate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium picosulphate (PICOPREP®) taken by participant prior to X-ray examination, endoscopy or surgery.
Trial: NCT01894984
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: This is an observational study. Risperidone will be administered as intramuscular injection at a starting dose of either 25 milligram (mg) or 37.5 mg or 50 mg (starting dose will be decided on the basis of the disease severity), every two weeks, up to Week 24, wherein after Week 8, dose may be increased or decreased at physician discretion. For first three weeks, previous oral antipsychotic drug (Benzodiazepines or Selective serotonin reuptake inhibitor \[SSRI\]) will be maintained and will cease at Week 3.
Trial: NCT00275535
Drug: Anti-thymocyte globulin
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoglobulin 1.5 mg/kg/d (days 0,1,2,4,6)
Trial: NCT00275535
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil 750 mg p.o. b.i.d.- maintenance
Trial: NCT00275535
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 500 mg/day initially, tapered to 5 mg/day by day 92
Trial: NCT00275535
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus - maintain trough levels of 6-8 ng/ml (whole blood Imx assay)
Trial: NCT02296281
Drug: Pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00275535
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rapamycin 3 to 5 mg/day; adjust to the high-performance liquid chromatography (HPLC) blood level 15 to 20 ng ml
Trial: NCT03835819
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab is an immunotherapy that activates a patient's own immune system to recognize and kill tumor cells
Trial: NCT03098355
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-2 of 250,000iu/m\^2 every other day for 2 weeks and then rest for 2 weeks for up to 6 months.
Trial: NCT01969643
Drug: ladiratuzumab vedotin
RxNorm normalized name: Ladiratuzumab vedotin
DrugBank: Ladiratuzumab vedotin (DB15409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LV will be given into the vein (IV; intravenously)
Trial: NCT01969643
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab will be given by IV every 3 weeks at a dose of 6 mg/kg (the first dose will be 8 mg/kg)
Trial: NCT02572583
Drug: Shufeng Jiedu Capsule
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02572583
Drug: Oseltamivir Phosphate Capsule
RxNorm normalized name: Oseltamivir Phosphate Capsules
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02413372
Drug: BMS-986036
RxNorm normalized name: BMS-986036
DrugBank: Pegbelfermin (DB15365)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00258284
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
Trial: NCT01331733
Drug: hMG + GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00882466
Drug: human recombinant erythropoietin
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous bolus injection of EPO (50unit/kg)
Trial: NCT00269594
Drug: Lamictal (lamotrigine)
RxNorm normalized name: Lamictal
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00261118
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 1g in 500 mls Normal Saline Placebo 500 mls Normal Saline
Trial: NCT01914731
Drug: Fecal Microbiota Transplant
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via frozen capsule
Trial: NCT02733237
Drug: oxytocin treatment
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intranasal administration of oxytocin (40 IU)
Trial: NCT02586051
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab 1000 milligrams (mg) IV infusion.
Trial: NCT00310778
Drug: high sodium diet
RxNorm normalized name: high-density polyethylene
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: high sodium diet
Trial: NCT00310778
Drug: low sodium diet
RxNorm normalized name: low-density polyethylene
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: low sodium diet
Trial: NCT00310778
Drug: ramipril 10 mg
RxNorm normalized name: ramipril 10 MG
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ramipril 10 mg
Trial: NCT00310778
Drug: valsartan 160 mg
RxNorm normalized name: valsartan 160 MG
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: valsartan 160 mg
Trial: NCT00310778
Drug: candesartan 8 mg
RxNorm normalized name: candesartan 8 mg oral tablet
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: candesartan 8 mg
Trial: NCT00310778
Drug: atenolol 50 mg
RxNorm normalized name: atenolol 50 MG
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atenolol 50 mg
Trial: NCT02586051
Drug: Intravenous Immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (2 grams per kilogram \[g/kg\]) IVIG (maximum 140 grams).
Trial: NCT01039844
Drug: LOC-paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase I Starting Dose: 100 mg/m\^2 IV (intravenously) 1 hour infusion on Day 1, 8, 15, 22 and 29; and repeated every 42 days (6 weeks) per cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I.
Trial: NCT00093782
Drug: temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT02497612
Drug: Artefenomel
RxNorm normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Granules for suspension Route of administration: oral
Trial: NCT00611533
Drug: atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.
Trial: NCT02043314
Drug: Isoniazida
RxNorm normalized name: Isoniazida
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01455831
Drug: Tinzaparin
RxNorm normalized name: Tinzaparin
DrugBank: Tinzaparin (DB06822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.
Trial: NCT01455831
Drug: Tinzaparin
RxNorm normalized name: Tinzaparin
DrugBank: Tinzaparin (DB06822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.
Trial: NCT01865188
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active comparator monotherapy doses
Trial: NCT01865188
Drug: LCZ696 and amlodipine combination
RxNorm normalized name: amlodipine and celecoxib
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental combination doses
Trial: NCT02777710
Drug: Pexidartinib
RxNorm normalized name: PEXIDARTINIB
DrugBank: Pexidartinib (DB12978)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
Trial: NCT02777710
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
Trial: NCT04666675
Drug: Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral; Tablet
Trial: NCT04666675
Drug: Placebo for Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral; Tablet
Trial: NCT02234570
Drug: Oxfendazole
RxNorm normalized name: Oxfendazole
DrugBank: Oxfendazole (DB11446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A benzimidazole carbamate antiparasitic drug. Oral Dose levels of 0.5,1, 3, 7.5, 15, 30, and 60 mg/kg will be evaluated sequentially, the dose increasing with each new cohort Group 1 to Group 7.
Trial: NCT01303861
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
Trial: NCT01303861
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive bupropion at a dose of 150mg once per day. Subsequently, the dose will be 150mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
Trial: NCT03850418
Drug: azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: azacitidine 32mg/m2 x 5 days every 28 days for minimum of 4 cycles if tolerated